Clinical Trial Update: Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update reports results for pembrolizumab (MK-3475) in surgically resectable head and neck squamous cell carcinoma. The study status is completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Cancer of Head and Neck, Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-05-11